1. In Vivo

The Quintessential Specialty Pharma, Valeant Embodies PE Tenets

Even as private equity firms reach into specialty pharma niche opportunities for deals, specialty pharma companies are evolving, as well. Valeant Pharmaceuticals is a very visible example of one kind of specialty pharma model, which is based as much upon sophisticated financial engineering as product growth.

Perhaps more than any other biopharma in recent years, Valeant Pharmaceuticals International Inc. has brought private equity (PE) tactics to bear as a strategic acquirer, explicitly relying solely on acquisitions rather than R&D to create exponential growth. It has emerged as a big cap in recent years, providing a vision centered on sophisticated business, rather than research, expertise. (SeeAlso see "Acquisitive Valeant Sheds Staff As It Closes Bausch & Lomb Deal" - Pink Sheet, 29 July, 2013..)

Since 2010, when it entered into a reverse merger with Biovail, Valeant has embarked on more than 25 company and asset acquisitions, many of them for marketed specialty pharma assets....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.